311 related articles for article (PubMed ID: 8910322)
21. Use of surface plasmon resonance for studies of protein-protein and protein-phospholipid membrane interactions. Application to the binding of factor VIII to von Willebrand factor and to phosphatidylserine-containing membranes.
Saenko E; Sarafanov A; Greco N; Shima M; Loster K; Schwinn H; Josic D
J Chromatogr A; 1999 Aug; 852(1):59-71. PubMed ID: 10480230
[TBL] [Abstract][Full Text] [Related]
22. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor.
Saenko EL; Scandella D
J Biol Chem; 1995 Jun; 270(23):13826-33. PubMed ID: 7775440
[TBL] [Abstract][Full Text] [Related]
23. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies.
Scandella D
Vox Sang; 1999; 77 Suppl 1():17-20. PubMed ID: 10529680
[TBL] [Abstract][Full Text] [Related]
24. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
25. Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin.
Hill-Eubanks DC; Parker CG; Lollar P
Proc Natl Acad Sci U S A; 1989 Sep; 86(17):6508-12. PubMed ID: 2505252
[TBL] [Abstract][Full Text] [Related]
26. Anti-heavy-chain monoclonal antibodies directed to the acidic regions of the factor VIII molecule inhibit the binding of factor VIII to phospholipids and von Willebrand factor.
Raut S; Villard S; Grailly S; Gilles JG; Granier C; Saint-Remy JM; Barrowcliffe TW
Thromb Haemost; 2003 Sep; 90(3):385-97. PubMed ID: 12958606
[TBL] [Abstract][Full Text] [Related]
27. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.
Jacquemin M; Benhida A; Peerlinck K; Desqueper B; Vander Elst L; Lavend'homme R; d'Oiron R; Schwaab R; Bakkus M; Thielemans K; Gilles JG; Vermylen J; Saint-Remy JM
Blood; 2000 Jan; 95(1):156-63. PubMed ID: 10607698
[TBL] [Abstract][Full Text] [Related]
28. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.
Gensana M; Altisent C; Aznar JA; Casaña P; Hernández F; Jorquera JI; Magallón M; Massot M; Puig L
Haemophilia; 2001 Jul; 7(4):369-74. PubMed ID: 11442641
[TBL] [Abstract][Full Text] [Related]
29. Replacing the factor VIII C1 domain with a second C2 domain reduces factor VIII stability and affinity for factor IXa.
Wakabayashi H; Fay PJ
J Biol Chem; 2013 Oct; 288(43):31289-97. PubMed ID: 24030831
[TBL] [Abstract][Full Text] [Related]
30. A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope.
Dimitrov JD; Roumenina LT; Plantier JL; Andre S; Saboulard D; Meslier Y; Planchais C; Jacquemin M; Saint-Remy JM; Atanasov BP; Kaveri SV; Lacroix-Desmazes S
J Thromb Haemost; 2010 Jul; 8(7):1524-31. PubMed ID: 20374449
[TBL] [Abstract][Full Text] [Related]
31. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.
Shima M; Scandella D; Yoshioka A; Nakai H; Tanaka I; Kamisue S; Terada S; Fukui H
Thromb Haemost; 1993 Mar; 69(3):240-6. PubMed ID: 7682339
[TBL] [Abstract][Full Text] [Related]
32. Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions.
Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
Thromb Res; 2021 Feb; 198():7-16. PubMed ID: 33248318
[TBL] [Abstract][Full Text] [Related]
33. Epitope specificity of anti-FVIII antibodies during immune tolerance therapy with factor VIII preparation containing von Willebrand factor.
Kallas A; Pooga M; Benhida A; Jacquemin M; Saint-Remy JM
Thromb Res; 2002 Sep; 107(6):291-302. PubMed ID: 12565716
[TBL] [Abstract][Full Text] [Related]
34. Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain.
Hamer RJ; Koedam JA; Beeser-Visser NH; Bertina RM; Van Mourik JA; Sixma JJ
Eur J Biochem; 1987 Jul; 166(1):37-43. PubMed ID: 3109914
[TBL] [Abstract][Full Text] [Related]
35. A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C-catalyzed inactivation.
Nogami K; Shima M; Nishiya K; Hosokawa K; Saenko EL; Sakurai Y; Shibata M; Suzuki H; Tanaka I; Yoshioka A
Blood; 2002 Jun; 99(11):3993-8. PubMed ID: 12010799
[TBL] [Abstract][Full Text] [Related]
36. Structural and functional characterization of platelet receptor-mediated factor VIII binding.
Ahmad SS; Scandura JM; Walsh PN
J Biol Chem; 2000 Apr; 275(17):13071-81. PubMed ID: 10777612
[TBL] [Abstract][Full Text] [Related]
37. Association of the factor VIII light chain with von Willebrand factor.
Lollar P; Hill-Eubanks DC; Parker CG
J Biol Chem; 1988 Jul; 263(21):10451-5. PubMed ID: 3134349
[TBL] [Abstract][Full Text] [Related]
38. The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets.
Nesheim M; Pittman DD; Giles AR; Fass DN; Wang JH; Slonosky D; Kaufman RJ
J Biol Chem; 1991 Sep; 266(27):17815-20. PubMed ID: 1917924
[TBL] [Abstract][Full Text] [Related]
39. Kinetic parameters of monoclonal antibodies ESH2, ESH4, ESH5, and ESH8 on coagulation factor VIII and their influence on factor VIII activity.
Egler C; Albert T; Brokemper O; Zabe-Kühn M; Mayer G; Oldenburg J; Schwaab R
J Mol Recognit; 2009; 22(4):301-6. PubMed ID: 19266540
[TBL] [Abstract][Full Text] [Related]
40. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes.
Gilles JG; Lavend'homme R; Peerlinck K; Jacquemin MG; Hoylaerts M; Jorieux S; Mazurier C; Vermylen J; Saint-Remy JM
Thromb Haemost; 1999 Jul; 82(1):40-5. PubMed ID: 10456452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
